XML 47 R40.htm IDEA: XBRL DOCUMENT v3.25.3
Fair Value of Financial Instruments - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jul. 19, 2024
Jul. 31, 2025
Sep. 30, 2025
Sep. 30, 2025
Dec. 31, 2024
Jul. 01, 2025
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]            
Shares sold during period     101,359,765 101,359,765 83,633,069  
Settlement agreement upfront payment $ 15,000,000          
Percentage of royalty payment 1.00%          
Settlement agreement upfront payment paid         $ 15,000,000  
Verve Therapeutics, Inc.            
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]            
Shares sold during period     546,970      
Total proceeds from shares     $ 5,700,000      
Realized loss on sale of marketable securities     400,000      
Other Than Verve Therapeutics Inc [Member]            
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]            
Realized gains or losses from the sale of marketable securities     0 $ 0    
Prime Medicine Inc            
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]            
Equity securities     $ 8,900,000 $ 8,900,000    
Prime Medicine Inc | Common Stock            
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]            
Equity shares held     1,608,337 1,608,337    
Acquisitions Completed            
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]            
Ownership Interest           100.00%
Total consideration paid   $ 14,500,000        
Upfront payment, shares   403,128        
Common stock valued           $ 6,700,000
Acquisitions Completed | In-Process Research and Development            
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]            
Research and development           14,500,000
Contingent Consideration Liabilities | Acquisitions Completed            
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]            
Seller transaction expenses           100,000
Contingent Consideration Liabilities | Acquisitions Completed | Maximum            
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]            
Potential milestone payments due contigent consideration           89,000,000
Level 3 | Contingent Consideration Liabilities | Acquisitions Completed            
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]            
Contingent consideration liabilities fair value           7,700,000
Development and Regulatory Milestones | Maximum            
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]            
Potential milestone payments due under settlement agreement $ 15,000,000          
Sales Milestone | Maximum            
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]            
Potential milestone payments due under settlement agreement $ 35,000,000          
Development, Clinical and Commerical Milestones | Acquisitions Completed            
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]            
Commercial milestones valued           $ 7,700,000